Melatonin and urological cancers: a new therapeutic approach.
Mohammad Hossein MehrzadiAzam HosseinzadehKobra Bahrampour JuybariSaeed MehrzadiPublished in: Cancer cell international (2020)
Urological cancers are responsible for thousands of cancer-related deaths around the world. Despite all developments in therapeutic approaches for cancer therapy, the absence of efficient treatments is a critical and vital problematic issue for physicians and researchers. Furthermore, routine medical therapies contribute to several undesirable adverse events for patients, reducing life quality and survival time. Therefore, many attempts are needed to explore potent alternative or complementary treatments for great outcomes. Melatonin has multiple beneficial potential effects, including anticancer properties. Melatonin in combination with chemoradiation therapy or even alone could suppress urological cancers through affecting essential cellular pathways. This review discusses current evidence reporting the beneficial effect of melatonin in urological malignancies, including prostate cancer, bladder cancer, and renal cancer.
Keyphrases
- prostate cancer
- cancer therapy
- urinary tract
- end stage renal disease
- newly diagnosed
- ejection fraction
- primary care
- healthcare
- papillary thyroid
- drug delivery
- prognostic factors
- stem cells
- type diabetes
- metabolic syndrome
- risk assessment
- skeletal muscle
- squamous cell carcinoma
- bone marrow
- anti inflammatory
- patient reported
- lymph node metastasis
- quality improvement
- free survival
- glycemic control